Multiplikator Forward P/S Prime Medicine, Inc. (PRME)
Prime Medicine, Inc. (PRME) possesses significant pricing power potential due to its DNA prime editing method. Stable capital reserves support intensive research and development. The shift in the projected P/S ratio visualizes these expectations, where the current value is 109.50. However, fierce competition in the gene editing field and patent disputes create serious risks for the long-term sustainability of the business.
PRME (Prime Medicine): rincian analitis lan laporan miturut indikator
- rega saiki lan proyeksi nilai saham:
- rincian kapitalisasi pasar:
- statistik nilai buku emiten:
- data tingkat utang lan likuiditas finansial:
Total Utang marang Modal Prime Medicine, Inc.|PRME - Kewajiban jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Prime Medicine|PRME - Kewajiban utang agregat|Utang-utang marang kapitalisasi buku Prime Medicine Corp|PRME - Gunggunge utang jangka dawa|Utang jangka cendhak perusahaan Prime Medicine|Rasio cepet primemedicine.com
- rincian asil keuangan lan kelipatan valuasi:
PRME - Penghasilan resik|Bathi mangsa ngarep Prime Medicine, Inc.|PRME - Periode bali modal bisnis|Rega marang bathi mangsa ngarep Prime Medicine Corp|PRME - Rasio kapitalisasi marang bathi lan wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Prime Medicine Inc|PRME - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Prime Medicine|PRME - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan primemedicine.com|PRME - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Prime Medicine, Inc.
- indikator volume dodolan lan pendapatan:
Ringkesan analisis perusahaan:Prime Medicine Bio PRME
Market expectation dynamics are critical for Prime Medicine, Inc. (PRME) amid fierce competition in the genome editing sector. The projected P/S metric compares current market capitalization with updated revenue forecasts to measure the premium for future growth. Daily price action regarding the projected P/S metric reflects investors' real-time assessment of patent risks and technological breakthroughs. High indicator values signal optimism, necessitating caution during sharp spikes.
Analisis perusahaan pesaing
Multiplikator Forward P/S TEM (Tempus Labs)|Qiagen N.V. - Rasio rega marang prakiraan pendapatan|IONS - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep repligen.com|RNA: Multiplikator Forward P/S|CRISPR Therapeutics Inc (CRSP) - Multiplikator Forward P/S|WGS (GeneDx Holdings) - Multiplikator Forward P/S|RARE: Rega forward marang dodolan|Multiplikator forward rega marang pendapatan BEAM (Beam Therapeutics Corp)|SRPT: Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S TWST (Twist Bioscience Inc)|Rasio kapitalisasi marang dodolan sing dikarepake 10x Genomics Corp (TXG)|intelliatx.com - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Stoke STOK|biolifesolutions.com (BLFS) - Rasio rega marang prakiraan pendapatan|WVE - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan MAZE|Multiplikator forward rega marang pendapatan Sionna Therapeutics, Inc. (SION)|Multiplikator Forward P/S TSHA|Multiplikator Forward P/S uniQure N.V. (QURE)|Rasio rega marang prakiraan pendapatan MeiraGTx Holdings plc MGTX|RGNX: Kapitalisasi marang prakiraan pendapatan|Solid Biosciences Inc - Multiplikator Forward P/S|OCGN - Multiplikator Forward P/S|PACB: Multiplikator Forward P/S|BNTC - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Design Therapeutics, Inc.|RCKT: Rega forward marang dodolan|Multiplikator forward rega marang pendapatan FDMT (4D Molecular Therapeutics, Inc.)|Lexeo Therapeutics, Inc. - Kapitalisasi marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Korro Bio, Inc. KRRO|EDIT: Kapitalisasi marang prakiraan pendapatan|SLN - Rasio rega marang prakiraan pendapatan|Prakiraan rega marang pendapatan ProQR Therapeutics (PRQR)|CDXS (Codexis Bio) - Multiplikator forward rega marang pendapatan|Sangamo Therapeutics Inc. (SGMO) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan Nautilus Bio|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Metagenomi Therapeutics MGX|Rasio rega marang prakiraan pendapatan Precision BioSciences (DTIL)|GBIO - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Multiplikator Forward P/S BOLD (Boundless Bio, Inc)|XCUR - Multiplikator forward rega marang pendapatan|IMNN - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Phio Pharmaceuticals Corp|MBIO: Multiplikator Forward P/S|TransCode (RNAZ) - Multiplikator Forward P/S|BNGO (Bionano) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Applied DNA Sciences, Inc. APDN|Multiplikator Forward P/S BLUE|ImmunoPrecise Antibodies Ltd - Kapitalisasi marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Omega Therapeutics OMGA|OMIC: Kapitalisasi marang prakiraan pendapatan|RGLS: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan SYRS (Syros Pharmaceuticals, Inc.)|Telesis Bio, Inc. (TBIO) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan TCON (TRACON)|Rasio rega marang prakiraan pendapatan Unity Biotechnology, Inc.
